Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Halberd Corp HALB

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s wholly owned subsidiary is Alaric Corporation.


OTCPK:HALB - Post by User

Comment by badgirl007on Jul 22, 2021 10:59am
37 Views
Post# 33587593

RE:Halbert corp. - greatest phantasy is not enough.

RE:Halbert corp. - greatest phantasy is not enough.YES YES YES - NEWS NEWS NEWS
 
Halberd Corp. Advances the Elimination of Antigens Present in Alzheimer’s Disease & PTSD/Chronic Traumatic Encephalopathy

 
Jackson Center, PA, July 22, 2021 – Halberd Corporation (OTC-PINK: “HALB“) confirms the shipment of samples of metallic nanoparticles conjugated to Alzheimer’s Disease (AD) antibodies, Tau and Phosphorylated Tau.  Having successfully conjugated the metallic nanoparticles (via its breakthrough patent-pending process), GreenBioAZ shipped the materials to Youngstown State University (YSU).  At YSU, Dr. William G. Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences Department and his team will immediately proceed to the next step – eradicating the conjugated AD building blocks via Halberd’s unique, proprietary laser eradication process.  This follows the promising results from initial tests with metal conjugated antibodies against E. coli.  Tau and Phosphorylated Tau have been linked to the formation of neurofibrillary tangles in the brain associated with Alzheimer’s Disease (AD).
 
William A. Hartman, Halberd’s Chairman, President & CEO, stated, “We are excited to begin testing to eliminate these first two building blocks associated with Alzheimer’s Disease.  We will continue our work on additional targeted proteins and cytokines associated with AD and PTSD/Chronic Traumatic Encephalopathy (CTE) while testing proceeds at the YSU laboratory. This close coordination of the respective, uniquely complementary talents at major universities, monitored by the talented Halberd scientific team, is now poised for this major, unparalleled step forward.
 
“Our Laser experimentation progressed more rapidly than our planned parallel, but alternative, experimentation using radio frequency (RF), because results to date have indicated the necessity to procure a stronger RF power unit.  We await the imminent delivery of that more powerful unit.  Additional parallel experimentation of an entirely different and simpler patent-pending Chemical Bonding Process awaits filing of provisional patent applications in process at the Ference Law Firm in Pittsburgh, Pennsylvania.”
 
Hartman added, “Dr. Felder, Halberd’s Chief Technology Officer and inventor, believes, as per numerous medical articles, that removal of two inflammatory cytokines, IL-6 and TNF-Alpha (already scheduled as part of the AD experimentation), may be the key to successfully treat PTSD and CTE.  Dr. Felder feels that this has been the key obstacle in the failure of all prior competitive endeavors to successfully treat PTSD.  We are now poised to eradicate these cytokines from cerebral spinal fluid (CSF) in our AD experimentation at YSU.  If our experimentation proves significant as a PTSD/CTE treatment, we will contact the Defense Advanced Research Projects Agency (DARPA) with our findings to seek potential joint development of our technology to address the PTSD-related suicide rate, which stands at almost one per hour by active and former military personnel.  An effective treatment for PTSD, and/or CTE, to eliminate suicide ideation has eluded the medical industry to date. Our technology applied via Halberd’s patented extracorporeal process offers a real opportunity to help those suffering from these terrible afflictions.”
 

Still undiscovered and simply not to be believed:

Whenever a company manages to develop an exclusive treatment method that no other pharmaceutical company is allowed to replicate,
 
then profits of several thousand, even several tens of thousands of percent are possible.
 
What do you think all investors would get out of a successful treatment for Alzheimer's disease?
 
And that would be just the beginning of the diseases that can be combated with their methods.

Do your own research.


https://halberdcorporation.com/news/

Currently still almost a gift!
https://www.otcmarkets.com/stock/HALB/profile

<< Previous
Bullboard Posts
Next >>